Crucially, this decrease was primarily attributable to a reduction in candy consumption, while chow intake increased compared to vehicle-treated controls with access to both food types (Raun et al., 2007)
About this article Cite this article Handelsman, Y., Muskiet, M.H.A
Key Takeaways Tesamorelin has FDA approval backed by two Phase 3 RCTs showing roughly 15 to 18 percent visceral fat reduction at 26 weeks in HIV-lipodystrophy patients (Falutz et al., 2007, 2010)
Future multicenter double-blind, randomized, placebo-controlled trials in a large and homogeneous sample of patients should focus on higher doses and more prolonged treatment
*Regular exercise and proper nutrition are essential components for achieving your fat loss goals